Mineralys Therapeutics, Inc. MLYS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$151.78M+19.5% | -$154.65M+13.0% | -$171.36M-11.8% | -$190.77M-59.4% | -$188.51M-108% | ||
| $50K0.0% | $59K+37.2% | $61K+118% | $57K+235% | $50K+525% | ||
| $22.23M+73.8% | $19.32M+70.5% | $17.17M+77.8% | $14.47M+78.7% | $12.79M+96.7% | ||
| —— | —— | —— | —— | —— | ||
| -$4.92M— | -$2.47M— | —— | —— | —— | ||
| -$71K+80.1% | $166K+139% | -$113K— | -$126K— | -$357K— | ||
| -$136.4M+29.2% | -$142.42M+14.4% | -$171.37M-33.4% | -$192.69M-98.0% | -$192.66M-120% | ||
| $692.5M+51.9% | $425M-13.0% | $407.5M+0.4% | $396M+20.9% | $456M+96.1% | ||
| $1.03B+174% | $814.74M+118% | $610.19M+59.5% | $368.55M-2.9% | $377.93M+22.5% | ||
| -$341.82M-538% | -$389.75M-439% | -$202.69M-970% | $27.42M+149% | $78.04M+197% | ||
| —— | —— | —— | —— | $189.46M— | ||
| $425.99M— | $591M— | $494.39M— | —— | —— | ||
| —— | —— | $120.32M— | $33.93M— | —— | ||
| $13.46M+69.5% | $9.88M+5.0% | $7.01M-30.8% | $7.32M-22.0% | $7.94M-6.8% | ||
| -$71K+80.1% | $166K+139% | -$113K— | -$126K— | -$357K— | ||
| -$4.92M— | -$2.47M— | —— | —— | —— | ||
| $1.03B+174% | $814.74M+118% | $610.19M+59.5% | $368.55M-2.9% | $377.93M+22.5% | ||
| $382K0.0% | $391K-10.1% | $133K-65.7% | $145K-58.2% | $382K+506% | ||
| —— | —— | —— | —— | -$32K— | ||
| —— | -$142.43M+14.4% | -$171.37M-33.3% | -$192.72M-98.0% | -$192.7M-120% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Mineralys Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.